All Articles

The FDA has confirmed another strong year regarding the approval of innovative new drugs and biosimilars, including several agents used in the treatment of patients with cancer.

We are incredibly enthusiastic about our growing community of navigators and the new heights we will reach together in 2020!

A 26-bed solid tumor oncology unit saw consistently low patient-satisfaction scores regarding education and discharge preparedness. Managers and staff wanted to improve patient education, without adding to the workflow of bedside nurses with a 4:1 patient/nurse ratio on a unit with rising acuity. Here’s how they approached the problem.

Navigators constantly hear the phase “standard of care,” but what does it essentially mean? Click here to find out.

Compared with other standard treatments, untreated patients with advanced non–small-cell lung cancer (NSCLC) who also have an EGFR mutation live longer when treated with osimertinib, according to a new study.

Keeping up with the numerous treatment advances in relapsed or refractory multiple myeloma can be a challenge for even the most informed providers, according to Jorge J. Castillo, MD, Clinical Director, Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.

Navigators from the American Cancer Society review and share their experience with establishing a hybrid approach to oncology navigation.

The future looks bright as new treatment modalities such as immunotherapy are developed, giving patients more options than ever before.

Nurse navigator Brenda Farmer writes about the powerful experience of showing up, standing up, and speaking up for those who can’t. Here’s her story.

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers.